EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study

Kimberly Martin, Mary E Norton, Cora MacPherson, Zachary Demko iD, Melissa Egbert, Sina Haeri, Fergal Malone, Ronald J Wapner, Ashley S Roman, Asma Khalil iD, Revital Faro, Rajeevi Madankumar and 8 more

Prenatal Diagnosis · 2023-12 · 43 (13) · 1574-1580

DOI: 10.1002/pd.6483 ↗

At a glance

Journal article in Prenatal Diagnosis, published online on 2023-12-08. Written by Kimberly Martin and 19 co-authors. Institution: Natera Inc., Austin, Texas, USA. Major MEDLINE topics: DiGeorge Syndrome, Cell-Free Nucleic Acids. Cited 3 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0). Funded by: Natera.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

One goal of prenatal genetic screening is to optimize perinatal care and improve infant outcomes. We sought to determine whether high‐risk cfDNA screening for 22q11.2 deletion syndrome (22q11.2DS) affected prenatal or neonatal management.

Methods

This was a secondary analysis from the SMART study. Patients with high‐risk cfDNA results for 22q11.2DS were compared with the low‐risk cohort for pregnancy characteristics and obstetrical management. To assess differences in neonatal care, we compared high‐risk neonates without prenatal genetic confirmation with a 1:1 matched low‐risk cohort.

Results

Of 18,020 eligible participants enrolled between 2015 and 2019, 38 (0.21%) were high‐risk and 17,982 (99.79%) were low‐risk for 22q11.2DS by cfDNA screening. High‐risk participants had more prenatal diagnostic testing (55.3%; 21/38 vs. 2.0%; 352/17,982, p < 0.001) and fetal echocardiography (76.9%; 10/13 vs. 19.6%; 10/51, p < 0.001). High‐risk newborns without prenatal diagnostic testing had higher rates of neonatal genetic testing (46.2%; 6/13 vs. 0%; 0/51, P < 0.001), echocardiography (30.8%; 4/13 vs. 4.0%; 2/50, p = 0.013), evaluation of calcium levels (46.2%; 6/13 vs. 4.1%; 2/49, P < 0.001) and lymphocyte count (53.8%; 7/13 vs. 15.7%; 8/51, p = 0.008).

Conclusions

High‐risk screening results for 22q11.2DS were associated with higher rates of prenatal and neonatal diagnostic genetic testing and other 22q11.2DS‐specific evaluations. However, these interventions were not universally performed, and >50% of high‐risk infants were discharged without genetic testing, representing possible missed opportunities to improve outcomes for affected individuals.

Subjects

MeSH terms (MEDLINE)

DiGeorge SyndromeCell-Free Nucleic AcidsPregnancyInfantFemaleHumansInfant, NewbornPrenatal DiagnosisGenetic Testing

Substances

Cell-Free Nucleic Acids

Authors and institutions

  • Natera Inc., Austin, Texas, USA.
  • Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA.
  • The Biostatistics Center, George Washington University, Washington, District of Columbia, USA.
  • Ouma Health, Park City, Utah, USA.
  • Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, New York, New York, USA.

ORCID profiles: Zachary Demko, Asma Khalil, Bo Jacobson, Pe'er Dar

Funding

  • Natera

Cite

APA

Martin, K., Norton, M. E., MacPherson, C., Demko, Z., Egbert, M., Haeri, S., Malone, F., Wapner, R. J., Roman, A. S., Khalil, A., Faro, R., Madankumar, R., Strong, N., Silver, R., Vohra, N., Hyett, J., Kao, C., Hakonarson, H., Jacobson, B., & Dar, P. (2023). Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study. Prenatal Diagnosis, 43(13), 1574-1580. https://doi.org/10.1002/pd.6483

Vancouver

Martin K, Norton ME, MacPherson C, Demko Z, Egbert M, Haeri S, et al. Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study. Prenatal Diagnosis. 2023;43(13):1574-1580. doi:10.1002/pd.6483

BibTeX
@article{Martin2023,
  author = {Martin, Kimberly and Norton, Mary E and MacPherson, Cora and Demko, Zachary and Egbert, Melissa and Haeri, Sina and Malone, Fergal and Wapner, Ronald J and Roman, Ashley S and Khalil, Asma and Faro, Revital and Madankumar, Rajeevi and Strong, Noel and Silver, Robert and Vohra, Nidhi and Hyett, Jon and Kao, Charlly and Hakonarson, Hakon and Jacobson, Bo and Dar, Pe'er},
  title = {Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study},
  journal = {Prenatal Diagnosis},
  year = {2023},
  volume = {43},
  number = {13},
  pages = {1574--1580},
  doi = {10.1002/pd.6483}
}
Start for free →